[Montelukast in treatment mild chronic asthma].

UNLABELLED: The efficacy of montelukast, a leukotriene receptor antagonist, in treatment of mild asthma was evaluated.

METHODS

Thirty children aged 6 to 14 years with mild persistent asthma (asthma history more than 12 months and > or = 15% FEV1 improvement after inhaled beta 2-agonist in the past, good control of asthma with inhaled cromolyn or budesonide in the last three months) were enrolled. The study included three periods (2 week's each): washout, placebo, and montelukast. Asthma symptoms score (range 0-5) and PEF were estimated twice daily by children. Spirometric parameters FEV1 and MEF50 were measured during three consecutive visits: on the day of study inclusion, on the last day of the placebo and montelukast period.

RESULTS

The mean value of asthma symptoms score was significantly lower during the montelukast period in comparison with placebo (p = 0.038). The mean PEF values were significantly higher during the montelukast vs. placebo period (p = 0.0091). Moreover, in the montelukast period, the mean PEF values in the second week were significantly higher than those in the first week (p = 0.003). The mean FEV1 predictive value in the last day of the montelukast period was higher, though not significantly, than on the day of study inclusion and on the last day of the placebo period. A similar change in mean MEF50 values was observed.

CONCLUSION

In children aged 6-14 years with mild persistent asthma, montelukast treatment significantly diminishes asthma symptoms and increases mean PEF values comparing to placebo.